AbbVie Inc. (NYSE:ABBV) - Page 2

Unbelievable Swings in Big Pharma Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Major Pharma Sees a Few Wild Swings in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Bad News for AbbVie and Multiple Myeloma Patients

AbbVie Inc. (NYSE: ABBV) and patients suffering from multiple myeloma have seen some additional bad news. The Food and Drug Administration (FDA) has placed a partial clinical hold on clinical ...
Read Full Story »

Big Pharma Short Interest Backs Off, With One Huge Exception

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Major Pharma Sees Tremendous Rise in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Why This New Collaboration Is Incredible for Voyager Therapeutics

On Friday, Voyager Therapeutics Inc. (NASDAQ: VYGR) announced a collaboration with pharma giant AbbVie Inc. (NYSE: ABBV) to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for ...
Read Full Story »

Major Pharma Scares Off Short Sellers

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Allergan, Apple, Carnival, Ciena, Juniper, Lockheed Martin, Plug Power, Take-Two, United Continental, Zynga and More

Stocks were indicated to open higher on Wednesday with positive earnings reactions from Apple and Boeing. Earnings season has been off to a mixed start at the start of 2019, ...
Read Full Story »

Reality Check: Big Biotech and Big Pharma Are Becoming Identical

There is great opportunity in healthcare. There is also quite a lot of risk. Politicians and consumers alike want lower drug prices. Patients want the best of the best options ...
Read Full Story »

Short Interest Spikes in a Couple Major Pharma Stocks

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

How AbbVie Tripped Up in Q4

When AbbVie Inc. (NYSE: ABBV) released its fourth-quarter financial results before the markets opened on Friday, the pharmaceutical giant said that it had $1.90 in earnings per share (EPS) and ...
Read Full Story »

Major Pharma Sees Fading Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Top Analyst Upgrades and Downgrades: AbbVie, Agilent, Albermarle, Apple, Boeing, Cheniere, First Solar, HCA, LabCorp, Lumber Liquidators, Teva and More

Stocks started 2019 on a mixed playing field on Wednesday, but Apple dropped a revenue and earnings warning after the close and that sent equity index futures down over 1% ...
Read Full Story »

Short Sellers Hike Bets in Major Pharma Stocks

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Major Pharma Stocks See a Surge in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »